July 29, 2021
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update
Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for the quarter… Read More
learn more
July 15, 2021
Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields… Read More
learn more
July 8, 2021
Novocure to Report Second Quarter 2021 Financial Results
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six… Read More
learn more
July 1, 2021
Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer
Disease control rate was 76% with 9.5% objective response in a patient population with poor prognosis and limited exposure to study treatments In patients who completed at least 12 weeks of Tumor Treating Fields treatment, disease control rate was 91% with 18% objective response Novocure plans… Read More
learn more
